Citations

Clear

3 citation(s) found for "Somers, Tamara".

Social risk factors predicting outcomes of cervical myelopathy surgery
Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Park, Paul , Alvi, Mohammed Ali , Alvi, Mohammed Ali , Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Turner, Jay D.

Mayo Clinic

Journal of Neurosurgery: Spine | February 18, 2022 | Volume: 37 | Issue: 1 | Pages: 41-48

10.3171/2021.12.spine21874 | PMID 35090132 Get It

OBJECTIVE Combinations of certain social risk factors of race, sex, education, socioeconomic status (SES), insurance, education, employment, and one’s housing situation have been associated with poorer pain and disability outcomes after lumbar spine surgery. To date, an exploration of such factors in patients with cervical spine surgery has not been conducted. The objective of the current work was to 1) define the social risk phenotypes of individuals who have undergone cervical spine surgery for myelopathy and 2) analyze their predictive capacity toward disability, pain, quality of life, and patient satisfaction–based outcomes. METHODS The Cervical Myelopathy Quality Outcomes Database was queried for the period from January 2016 to December 2018. Race/ethnicity, educational attainment, SES, insurance payer, and employment status were modeled into unique social phenotypes using latent class analyses. Proportions of social groups were analyzed for demonstrating a minimal clinically important difference (MCID) of 30% from baseline for disability, neck and arm pain, quality of life, and patient satisfaction at the 3-month and 1-year follow-ups. RESULTS A total of 730 individuals who had undergone cervical myelopathy surgery were included in the final cohort. Latent class analysis identified 2 subgroups: 1) high risk (non-White race and ethnicity, lower educational attainment, not working, poor insurance, and predominantly lower SES), n = 268, 36.7% (class 1); and 2) low risk (White, employed with good insurance, and higher education and SES), n = 462, 63.3% (class 2). For both 3-month and 1-year outcomes, the high-risk group (class 1) had decreased odds (all p < 0.05) of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Being in the low-risk group (class 2) resulted in an increased odds of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Neither group had increased or decreased odds of being satisfied with surgery. CONCLUSIONS Although 2 groups underwent similar surgical approaches, the social phenotype involving non-White race/ethnicity, poor insurance, lower SES, and poor employment did not meet MCIDs for a variety of outcome measures. This finding should prompt surgeons to proactively incorporate socially conscience care pathways within healthcare systems, as well as to optimize community-based resources to improve outcomes and personalize care for populations at social risk.
Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness
Tjia, Jennifer , Kutner, Jean S. , Kendrick, Rachael, Prince‐Paul, Maryjo , McPherson, Mary Lynn , Sloan, Jeff A. , Furuno, Jon P. , Ritchie, Christine Seel , Blatchford, Patrick Jud , Somers, Tamara J. , Abernethy, Amy P.

Mayo Clinic

Journal of Palliative Medicine | May 18, 2017 | Volume: 20 | Issue: 10 | Pages: 1098-1103

10.1089/jpm.2016.0489 | PMID 28520522 Get It

Discontinuing chronic medications: Perceptions of patients with life-limiting illness.
Kutner, Jean S. , McPherson, Mary Lynn , Sloan, Jeff A. , Abernethy, Amy Pickar, Ritchie, Christine Seel , Furuno, Jon P. , Prince‐Paul, Maryjo , Tjia, Jennifer , Somers, Tamara J. , Blatchford, Patrick Jud

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 32 | Issue: 31_suppl | Pages: 97-97

10.1200/jco.2014.32.31_suppl.97 Get It

97 Background: Optimal management of chronic medications is uncertain in life-limiting illness. To inform shared decision making, we assessed patient perceptions in a trial on the safety of discontinuing statins in life-limiting illness. Methods: Eligible adults (life expectancy 1–12 months, on statin for ≥ 3 months for primary/secondary prevention, recent functional decline, no active cardiovascular disease) were randomized to discontinue or continue statins and were followed monthly for up to 1 year. Cognitively intact participants were asked 9 questions regarding discontinuing statins prior to randomization. We used Pearson chi-square to compare responses between study groups and between those with and without cancer. Of 381 participants, 297 (78%) were cognitively intact (138 discontinued, 159 continued statins). Mean age was 72 years (SD 11) and mean number of medications used was 11.5 (SD 5.0); 58% (N = 173) had cancer. Results: There were no statistically significant differences between the study groups in responses to the medication perception questions. Aggregate findings are presented (Table). Patients with cancer were less likely to think that they may be able to stop other medications (28% vs. 42%, p=0.007) and that statin discontinuation means that the doctor is giving up on them (1% vs. 7%, p=0.013). Conclusions: Few participants expressed concerns about discontinuing statins; many perceived potential benefits. Cancer patients may perceive less impact from stopping statins. Clinicians should inquire about patient concerns when engaging in shared decision making about discontinuing chronic medications in the setting of advanced cancer. Clinical trial information: NCT01415934. [Table: see text]